SCHEMBL16739617

SCHEMBL16739617

Cc1nc2ccc(F)cc2n1-c1cccc(Nc2ccc(Cl)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 6/20 0.49
MAP3K14 Q99558 1/20 0.44
AGPAT2 O15120 1/20 0.42
GSR P00390 1/20 0.41
DHFR P00374 2/20 0.41
EGFR P00533 1/20 0.39
ERBB3 P21860 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
LCK P06239 1/20 0.37
PIK3CA P42336 1/20 0.37
SCN9A Q15858 1/20 0.37
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
GSK3B P49841 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740054 0.91 BMI1 (0.51) BMI1DHFRJAK2JAK3MEN1
SCHEMBL16739717 0.88 EGFR (0.40) BMI1MAP3K14AGPAT2DHFREGFR
SCHEMBL16739861 0.87 BMI1 (0.52) BMI1DHFRPIK3CARAB9AMEN1
SCHEMBL16747853 0.87 BMI1 (0.66) BMI1JAK2JAK3PIK3CA
SCHEMBL16739654 0.86 BMI1 (0.47) BMI1JAK2JAK3PIK3CAGSK3B
SCHEMBL16739769 0.86 BMI1 (0.53) BMI1MAP3K14AGPAT2GSRDHFR
SCHEMBL16740282 0.85 BMI1 (0.50) BMI1PIK3CARAB9AGSK3BNPC1
SCHEMBL16740171 0.84 BMI1 (0.67) BMI1SCN9A
SCHEMBL16740150 0.84 BMI1 (0.50) BMI1DHFR
SCHEMBL16740068 0.83 BMI1 (0.45) BMI1PIK3CARAB9AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
EP-3071553-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC Therapeutics, Inc. (US) 2016-09-28 EP disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885MAP3K14 1733/4885AGPAT2 4306/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B BMI1 1/4885MAP3K14 1733/4885AGPAT2 4306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.